Question to the HM Treasury:

To ask the Chancellor of the Exchequer, with reference to the UK Internal Market System, how many unclosed supplementary declarations were there on 1 October 2025.

Answered by Dan Tomlinson - Exchequer Secretary (HM Treasury)

There are several facilitations available to businesses moving goods within the UK Internal Market System. Businesses can choose to make use of Simplified Customs Declaration Processes (SCDP), such as the Entry in Declarants Records (EIDR) process when moving goods into Northern Ireland. This allows businesses to have up until the 10th calendar day of the month following the goods entering Northern Ireland to submit a supplementary declaration. HMRC cannot provide the number of unclosed supplementary declarations as HMRC does not have direct access to all traders’ records that make use of EIDR. HMRC continues to support businesses to comply with their legal obligations.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what discussions she has had with Ofcom on the impact of Physical Infrastructure Access costs on the deployment of fibre optic broadband in rural areas.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

As the independent regulator for telecommunications, Ofcom is responsible for making regulatory decisions in the fixed telecoms sector, including on the Physical Infrastructure Access (PIA) product.

My officials are regularly engaging with Ofcom to ensure that we have the right regulatory environment in place to promote competition and investment in the fibre roll-out across the UK, including in rural areas.

In July, we published our draft Statement of Strategic Priorities for telecommunications, the management of radio spectrum, and postal services that sets out the Government’s view on infrastructure sharing in the fixed telecoms sector, including asking Ofcom to demonstrate greater transparency in how they calculate and set PIA prices.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, whether Ofcom will review Physical Infrastructure Access pricing in the Telecoms Access Review.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

As the independent regulator for telecommunications, Ofcom is responsible for making regulatory decisions in the fixed telecoms sector, including on the Physical Infrastructure Access (PIA) product.

My officials are regularly engaging with Ofcom to ensure that we have the right regulatory environment in place to promote competition and investment in the fibre roll-out across the UK, including in rural areas.

In July, we published our draft Statement of Strategic Priorities for telecommunications, the management of radio spectrum, and postal services that sets out the Government’s view on infrastructure sharing in the fixed telecoms sector, including asking Ofcom to demonstrate greater transparency in how they calculate and set PIA prices.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of high launch prices set by major pharmaceutical firms on NICE’s cost-effectiveness assessments; and what steps are being taken to prevent such pricing from restricting patient access to new treatments.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations, normally within three months of the publication of final guidance.

NICE’s process ensures that new licensed medicines will only be routinely funded by the NHS where the evidence demonstrates that their costs are justified by the benefits that they bring for NHS patients. As part of NICE’s appraisal process, companies are able to propose patient access schemes to improve their value proposition with the aim of securing a positive NICE recommendation. NICE is able to recommend the vast majority of the medicines that it appraises, with 91% of medicines recommended for the NHS use in the last year.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, what steps she is taking to ensure clear and timely public communication to farmers and pet owners in Northern Ireland on changes to the availability and prescribing of veterinary medicines after 31 December 2025.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

The Government has been taking steps to support businesses and end-users in preparation ahead of 1 January. This includes communications to the farming sector and pet owners. The department published guidance, including a manual with specific information for pet owners and farmers.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, what steps her Department is taking to provide real-time operational guidance to veterinary practices and Suitably Qualified Persons in Northern Ireland on product availability changes after 31 December 2025.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

Guidance was published in June and recently updated reflecting industry feedback; the updated guidance that was published included specific references to vets and suitably qualified persons.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment her Department has made of the adequacy of the readiness of (a) veterinary practices and (b) farm businesses in Northern Ireland for changes to regulations on veterinary medicines.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

We continue to engage extensively with industry stakeholders across the supply chain to support them with continued availability of veterinary medicines beyond the grace period. This includes engagement with veterinary and farmer associations and businesses. The Government has also issued extensive guidance and intends to publish several webinars shortly. This guidance provides information to help veterinary practices and farm businesses prepare.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, when final commercial decisions from manufacturers on veterinary medicine product availability in Northern Ireland will be communicated to veterinary practices and Suitably Qualified Persons.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

Most pharmaceutical companies have already taken or are taking steps to make the required adjustments so we are confident that the disruption to veterinary medicines supply will be limited. Several larger companies have also communicated these decisions publicly.

For those that have not, we continue to strongly encourage them to inform businesses as soon as possible about their intentions.

However, following extensive stakeholder engagement, our assessment shows that most products currently on the Northern Ireland market will still be available. We have identified fewer than 20 products where discontinuation would pose significant risks to animal health and welfare if these risks were not addressed; the two schemes that we are introducing will serve to address those risks.

Although these figures may change as pharmaceutical companies take steps to adjust before the end of the year, we are not expecting to see a significant change and continue to monitor the situation closely.

Question to the Northern Ireland Office:

To ask the Secretary of State for Northern Ireland, pursuant to the Answer of 17 November 2025 to Question 90013 on UK Internal Trade, with reference to the Windsor Framework Independent Monitory Panel Report on the first reporting period for the UK Internal Market Guarantee for 1 January - 30 June 2025, what proportion of the 96% movements by value moved without the payment of a duty (a) were made in compliance with (i) Commission Delegated Regulation (EU) 2023/1128 of 24 March 2023 and (ii) Regulation (EU) 2023/1231 of the European Parliament and of the Council of 14 June 2023 and (b) were made under the full EU Customs Code, Regulation (EU) No 952/2013 of the European Parliament and of the Council of 9 October 2013.

Answered by Hilary Benn - Secretary of State for Northern Ireland

The role of the Independent Monitoring Panel does not cover reporting on the legislative basis under which movements between Great Britain and Northern Ireland take place.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, whether her Department will assess the potential impacts of the (a) Veterinary Medicines Internal Market Scheme and (b) Veterinary Medicines Health Situations Scheme on the agri-food supply chain in Northern Ireland during the first year of implementation.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

We are confident in the two schemes being introduced by the Government and will continue to closely monitor the situation over the upcoming year and beyond. After extensive stakeholder engagement, our current assessment is that there will be minimal disruptions to veterinary medicines in Northern Ireland and the agri-food supply chain will continue as it is now.

The two schemes will take effect from 1 January, and we will monitor their effectiveness.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, what information her Department holds on the prevalence of non-stun slaughter for Halal meat production in each year since 2015; and whether she has received representations from relevant stakeholders on animal welfare standards.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

UK data regarding the number or proportion of animals slaughtered using the halal method without prior stunning is not collected.

The Food Standards Agency carries out a periodic slaughter sector survey in England and Wales, which started in 2011. Links to previous slaughter sector surveys are available here.

The Department has regular engagement with stakeholders on animal welfare standards.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps the Government is taking through the UK Life Sciences Industrial Strategy to prevent incentives or regulatory reforms from enabling large pharmaceutical companies to increase medicine prices; and whether the Government will publish an impact assessment of how current industry pricing behaviours influence NHS drug costs and UK supply-chain resilience.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) controls the cost of sales of branded medicines to the National Health Service. The VPAG has a variable headline payment percentage, which accounts for changes to the cost of medicine sales to the NHS. The VPAG also contains a mechanism for allowing price increases for specific medicines. No scheme member may increase the NHS list price of any medicine without the Department’s prior approval.

Investing in the newest medicines so that patients can get access to life saving treatments is a critical part of a modern health care system and one that many charities and patient groups frequently call for. As part of our Life Sciences Sector Plan, we've committed to working with industry to accelerate growth in net spend on innovative medicines compared to the previous decade.

The resilience of United Kingdom supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver solutions. However, medicine shortages are a complex and global issue and everyone in the supply chain has a role to play in addressing them, with any action requiring a collaborative approach.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of how major pharmaceutical companies’ pricing strategies affect the VPAG’s ability to control NHS spending; and what steps are being taken to prevent higher drug costs.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) controls the cost of sales of branded medicines to the National Health Service. The VPAG has a variable headline payment percentage, which accounts for changes to the cost of medicine sales to the NHS. The VPAG also contains a mechanism for allowing price increases for specific medicines. No scheme member may increase the NHS list price of any medicine without the Department’s prior approval.

Investing in the newest medicines so that patients can get access to life saving treatments is a critical part of a modern health care system and one that many charities and patient groups frequently call for. As part of our Life Sciences Sector Plan, we've committed to working with industry to accelerate growth in net spend on innovative medicines compared to the previous decade.

The resilience of United Kingdom supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver solutions. However, medicine shortages are a complex and global issue and everyone in the supply chain has a role to play in addressing them, with any action requiring a collaborative approach.

Anniversary of the murder of Ken Smyth and Daniel McCormick

Cancelled mayoral elections

International Day of Human Rights and the persecution of Christians

Asylum reform proposals

Thanking postal workers

Russian shadow fleet

Non-stun slaughter ban

National debt

Freezing tax thresholds

Welfare benefits for foreign nationals

Trial by jury

Royal Kennel Club

20th anniversary of the death of George Best

New private capital in the NHS in the Autumn Budget

Crohn’s and Colitis Awareness Week 2025

Collection and publication of nationality data by Government Departments